DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?
What is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?
By Editor